NovaBay Pharmaceuticals $NBY announced that it has reclaimed compliance with the NYSE MKT continued listing standards. On April 28th 2015, the drug-maker received notice which said that it was out of compliance with Section 1003 (a) (i) of the NYSE MKT Company Guide pertaining to shareholder equity requirements. Nonetheless, the company, through a series of financings has been able to generate more than $300 million to reclaim compliance and maintain its listings on the exchange.